Zobrazeno 1 - 10
of 144
pro vyhledávání: '"Bifeprunox"'
Publikováno v:
International Journal of Molecular Sciences, Vol 17, Iss 4, p 459 (2016)
Aripiprazole, a dopamine D2 receptor (D2R) partial agonist, possesses a unique clinical profile. Glycogen synthase kinase 3β (GSK3β)-dependent signalling pathways have been implicated in the pathophysiology of schizophrenia and antipsychotic drug a
Externí odkaz:
https://doaj.org/article/be3e72262e224296bfeca010b990daa7
Publikováno v:
Journal of Molecular Neuroscience. 59:36-47
The GABAA receptor is implicated in the pathophysiology of schizophrenia and regulated by PKA signalling. Current antipsychotics bind with D2-like receptors, but not the GABAA receptor. The cAMP-responsive element-binding protein 1 (CREB1) is also as
Autor:
Sarah R. Davies
Publikováno v:
Cochrane Clinical Answers.
Publikováno v:
Psychopharmacology. 236(9)
Antipsychotics exert therapeutic effects by modulating various cellular signalling pathways and several types of receptors, including PKA- and GSK3β-mediated signalling pathways, and NMDA receptors. The ventral midbrain, mainly containing the ventra
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences; Volume 17; Issue 4; Pages: 459
International Journal of Molecular Sciences, Vol 17, Iss 4, p 459 (2016)
International Journal of Molecular Sciences; Volume 17; Issue 4; Pages: 459
International Journal of Molecular Sciences, Vol 17, Iss 4, p 459 (2016)
Aripiprazole, a dopamine D₂ receptor (D₂R) partial agonist, possesses a unique clinical profile. Glycogen synthase kinase 3β (GSK3β)-dependent signalling pathways have been implicated in the pathophysiology of schizophrenia and antipsychotic dr
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Current Medicinal Chemistry. 21:437-457
Psychiatric disorders like schizophrenia and neurodegenerative diseases like Parkinson's disease are associated with poly-factorial pathogenic mechanisms, with several neurotransmitter systems closely involved. In addition to the cerebral dopaminergi
Publikováno v:
Psychopharmacology. 226:285-293
Rationale Cariprazine (RGH-188) is a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate for the treatment of schizophrenia and bipolar mania. Substance abuse is a frequent comorbidity of both disorders and is associated wit
Publikováno v:
The Cochrane Library
Background Bifeprunox is a novel antipsychotic drug designed to treat schizophrenia. However, research into the drug was ceased in 2009 due to rejection of licence to go to market by the US Food and Drug Administration (FDA), who could not approve th
Publikováno v:
Scientific Reports
Aripiprazole is a D2-like receptor (D2R) partial agonist with a favourable clinical profile. Previous investigations indicated that acute and short-term administration of aripiprazole had effects on PKA activity, GSK3β-dependent pathways, GABAA rece